Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

Epidermal growth factor receptor (EGFR) and EGFRvIII analysis is of current interest in glioblastoma – the most common malignant primary CNS tumor, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K–Akt pathways, and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signaling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and pre-clinical RNA-based therapies, and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoral heterogeneity.

• Publication year

  2015

• Venue

  Frontiers in Oncology

• Publication date

  2015-01-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2015.00005PMID 25688333PMCID 4310282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Social network.

  2015cited by this paper
• A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

  2015cited by this paper
• Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

  2014cited by this paper
• Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

  2014influential reference
• Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

  2014cited by this paper
• Current management of advanced melanoma: a transformed landscape

  2014cited by this paper
• The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review

  2014cited by this paper
• Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro

  2014cited by this paper
• Pazopanib for the treatment of advanced renal cell cancer

  2014cited by this paper
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• The role of GM-CSF in enhancing immunotherapy of cancer.

  2013cited by this paper
• EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

  2013influential reference
• MicroRNA in Human Glioma

  2013cited by this paper
• EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

  2013cited by this paper
• Nimotuzumab treatment of malignant gliomas

  2012influential reference
• Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

  2012cited by this paper
• Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas

  2012cited by this paper
• Transferrin Antibodies Into the Brain

  2012cited by this paper
• Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

  2012cited by this paper
• Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

  2012cited by this paper
• Targeting the EGFR-family for therapy: biological challenges and clinical perspective.

  2012cited by this paper
• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  2012cited by this paper
• Glioblastoma survival in the United States before and during the temozolomide era

  2012cited by this paper
• microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling.

  2011cited by this paper
• Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

  2011cited by this paper
• Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

  2011influential reference
• Heterogeneity maintenance in glioblastoma: a social network.

  2011cited by this paper
• Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence

  2011cited by this paper
• Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells

  2011cited by this paper
• EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

  2011cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

  2010cited by this paper
• Escape from targeted inhibition: the dark side of kinase inhibitor therapy.

  2010cited by this paper
• RNA interference therapy for glioblastoma

  2010cited by this paper
• A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.

  2010cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010cited by this paper
• Systems Biology: An Approach

  2010cited by this paper
• A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

  2009cited by this paper
• The EGFRvIII variant in glioblastoma multiforme.

  2009cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.

  2009cited by this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cited by this paper
• Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

  2009cited by this paper
• Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

  2009influential reference
• EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma

  2009cited by this paper
• Microtubules modulate melatonin receptors involved in phase‐shifting circadian activity rhythms: in vitro and in vivo evidence

  2009cited by this paper
• An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2008cited by this paper
• microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.

  2008cited by this paper
• Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.

  2007cited by this paper
• Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.

  2007cited by this paper
• PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007influential reference
• Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach

  2007cited by this paper
• Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

  2007cited by this paper
• Receptor tyrosine kinases as therapeutic targets in malignant glioma.

  2007cited by this paper
• Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

  2007cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

  2007cited by this paper
• Temozolomide as a vaccine adjuvant in GBM

  2007influential reference
• Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo

  2006influential reference
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Function of aberrant EGFR in malignant gliomas

  2006cited by this paper
• Activation of STAT3, MAPK, and AKT in Malignant Astrocytic Gliomas: Correlation With EGFR Status, Tumor Grade, and Survival

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

  2006cited by this paper
• Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

  2006cited by this paper
• Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.

  2006influential reference
• The natural history of EGFR and EGFRvIII in glioblastoma patients

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.

  2004cited by this paper
• IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells.

  2004cited by this paper
• IκBαM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells

  2004cited by this paper
• The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

  2004influential reference
• The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

  2004cited by this paper
• EGFR mutations and sensitivity to gefitinib.

  2004cited by this paper
• EGFR mutations and sensitivity to gefitinib.

  2004cited by this paper
• Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas.

  2004cited by this paper
• Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

  2003cited by this paper
• Inhibition of glioma growth by tumor-specific activation of double-stranded RNA–dependent protein kinase PKR

  2002cited by this paper
• Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme

  2002cited by this paper
• Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

  2002cited by this paper
• Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

  2002cited by this paper
• Radioiodinated (I-125) Monoclonal Antibody 425 in the Treatment of High Grade Glioma Patients: Ten-Year Synopsis of a Novel Treatment

  2002cited by this paper
• Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.

  2000cited by this paper
• Inhibition by the Bioflavonoid Ternatin of Aflatoxin B1‐induced Lipid Peroxidation in Rat Liver

  1999cited by this paper
• Inhibitory effect of EGFR antisense RNA on growth of glioma cells in vitro

  1998cited by this paper
• Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression.

  1998cited by this paper
• A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

  1996cited by this paper

• Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes

  2026cites this paper
• Practical and translational therapeutic elements for GBM therapy.

  2026cites this paper
• The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma

  2026cites this paper
• CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.

  2026cites this paper
• CAR-T Cell Therapy for Central Nervous System Tumors.

  2026cites this paper
• Biomimetic extracellular vesicles derived from chimeric antigen receptor monocytes to treat glioblastoma: An efficient and safe intranasal drug delivery nanoplatform

  2025cites this paper
• Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell

  2025cites this paper
• Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress

  2025cites this paper
• The microenvironment of glioblastoma: in pursuit of universal multimodal immunotherapy.

  2025cites this paper
• Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression

  2025cites this paper
• Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy

  2025cites this paper
• Insights into extracellular vesicle-based platforms on the way to cancer treatment

  2025cites this paper
• Comprehensive review on glioblastoma: nanotechnology, immunotherapy and combined therapeutic approaches

  2025cites this paper
• Glioblastoma at the crossroads: current understanding and future therapeutic horizons

  2025cites this paper
• Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines

  2024cites this paper
• Glioblastoma: A molecular insight into current discoveries and treatment directions

  2024cites this paper
• A review of prognostic molecular biomarkers for glioblastoma and their clinical significance for diagnosis and treatment

  2024cites this paper
• Impact of GRM7 Gene Variations on Glioblastoma Risk in the Iranian Population.

  2024cites this paper
• Epidermal Growth Factor Receptor (EGFR) Inhibitors Screened from Autodisplayed Fv-Antibody Library.

  2024cites this paper
• Regional and intratumoral adoptive T-cell therapy

  2024cites this paper
• Ethanol extract of Vanilla planifolia stems reduces PAK6 expression and induces cell death in glioblastoma cells

  2024cites this paper
• Advances in CAR-T therapy for central nervous system tumors

  2024cites this paper
• T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression

  2024cites this paper
• Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

  2024cites this paper
• Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis

  2024cites this paper
• GBM Immunotherapy: Macrophage Impacts

  2024cites this paper
• Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review.

  2024cites this paper
• Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation

  2024cites this paper
• Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research

  2024cites this paper
• PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models

  2024cites this paper
• Optimizing CAR-T Therapy for Glioblastoma

  2023cites this paper
• Recent updates on thienopyrimidine derivatives as anticancer agents

  2023cites this paper
• Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures

  2023cites this paper
• Bioinformatics approach to identify the impacts of microgravity on the development of bone and joint diseases

  2023cites this paper
• Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line

  2023cites this paper
• Immunotherapy for Recurrent Glioma—From Bench to Bedside

  2023cites this paper
• Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape

  2023cites this paper
• Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach.

  2023cites this paper
• Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas

  2023cites this paper
• From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

  2023cites this paper
• Outsmarting refractory glioblastoma using in silico guided, phage display derived peptides targeting oncogenic EGFRvIII

  2023cites this paper
• An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma

  2023cites this paper
• Splice-Switching Antisense Oligonucleotides Targeting Extra- and Intracellular Domains of Epidermal Growth Factor Receptor in Cancer Cells

  2023cites this paper
• EGFR alterations in glioblastoma play a role in antitumor immunity regulation

  2023cites this paper
• N6-Isopentenyladenosine Impairs Mitochondrial Metabolism through Inhibition of EGFR Translocation on Mitochondria in Glioblastoma Cells

  2022cites this paper
• N6-isopentenyladenosine induces cell death through necroptosis in human glioblastoma cells

  2022cites this paper
• Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

  2022influential citation
• The Role of Micro RNAs in Regulating PI3K/AKT Signaling Pathways in Glioblastoma

  2022cites this paper
• The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

  2022cites this paper
• Multi-Targeting Approach in Glioblastoma Using Computer-Assisted Drug Discovery Tools to Overcome the Blood–Brain Barrier and Target EGFR/PI3Kp110β Signaling

  2022cites this paper
• Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers

  2022cites this paper
• The story of EGFR: from signaling pathways to a potent anticancer target.

  2022cites this paper
• The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification

  2022cites this paper
• PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

  2022cites this paper
• Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics

  2022cites this paper
• Emerging immune-based technologies for high-grade gliomas

  2022cites this paper
• N6-isopentenyladenosine induces cell death through necroptosis in human glioblastoma cells

  2022cites this paper
• Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations

  2022cites this paper
• Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cells—Literature Review

  2022cites this paper
• Recent trends in the development of hydrogel therapeutics for the treatment of central nervous system disorders

  2022cites this paper
• The Metalloprotease-Disintegrin ADAM8 Alters the Tumor Suppressor miR-181a-5p Expression Profile in Glioblastoma Thereby Contributing to Its Aggressiveness

  2022cites this paper
• Regulation of receptors Siglec-11 and Siglec- 15 by microRNAs and their overall effect on glioblastoma

  2022cites this paper
• Immunotherapy of glioblastoma: Recent advances and future prospects

  2022cites this paper
• Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines

  2022influential citation
• Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity

  2021cites this paper
• CAR T Cells.

  2021cites this paper
• Pre-Clinical Models and Potential Novel Therapies for Glioblastomas

  2021cites this paper
• Advances in Immunotherapy for Adult Glioblastoma

  2021cites this paper
• Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update

  2021cites this paper
• The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas

  2021cites this paper
• Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.

  2021cites this paper
• Computational methods for characterizing and learning from heterogeneous cell signaling data.

  2021cites this paper
• Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I)

  2021cites this paper
• Updated Insights on EGFR Signaling Pathways in Glioma

  2021cites this paper
• Current Approaches for Glioma Gene Therapy and Virotherapy

  2021cites this paper
• Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)

  2021cites this paper
• Targeting glioblastoma: from dream to reality.

  2021cites this paper
• Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide

  2021cites this paper
• Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem

  2021cites this paper
• Safety and Efficacy Assessments to Take Antioxidants in Glioblastoma Therapy: From In Vitro Experiences to Animal and Clinical Studies.

  2021cites this paper
• Surface-Modified Nanodrug Carriers for Brain Cancer Treatment

  2020cites this paper
• Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma

  2020cites this paper
• GLIOBLASTOMA MULTIFORME: A META-ANALYSIS OF DRIVER GENES, CURRENT DIAGNOSIS, AND TUMOR HETEROGENEITY

  2020cites this paper
• Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.

  2020cites this paper
• EGFR forms ligand-independent oligomers that are distinct from the active state

  2020cites this paper
• Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death

  2020cites this paper
• In vitro antitumor effect of cucurbitacin E on human lung cancer cell line and its molecular mechanism.

  2020cites this paper
• The current state of potential therapeutic modalities for glioblastoma multiforme: a clinical review.

  2020cites this paper
• Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics

  2020cites this paper
• Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme

  2020cites this paper
• ERK-mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells.

  2020cites this paper
• Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth

  2020cites this paper
• Ligand-independent EGFR oligomers do not rely on the active state asymmetric kinase dimer

  2020cites this paper
• The update of chimeric antigen receptor (CAR) -T cells therapy in Glioblastoma.

  2020cites this paper
• Brief Overview of Chimeric Antigen Receptor–Mediated Immunotherapy for Glioblastoma Multiforme

  2020cites this paper
• Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study

  2020cites this paper
• Fecal Akkermansia muciniphila Is Associated with Body Composition and Microbiota Diversity in Overweight and Obese Women with Breast Cancer Participating in a Presurgical Weight Loss Trial.

  2020cites this paper
• Quantification of the Underlying Mechanisms and Relationships Among Cancer, Metastasis, and Differentiation and Development

  2020cites this paper
• Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges

  2020cites this paper
• Demeclocycline Reduces the Growth of Human Brain Tumor-Initiating Cells: Direct Activity and Through Monocytes

  2020cites this paper